CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis - PubMed

Affiliations

• PMID: 17083975
• DOI: 10.1016/j.molimm.2006.09.032

Comparative Study

CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis

Michael Mølhøj et al. Mol Immunol. 2007 Mar.

Abstract

Many kinds of bispecific antibodies recruiting T cells for cancer therapy have been developed. Side-by-side comparison has shown that CD19-/CD3-bispecific antibodies of the diabody, tandem diabody (Tandab) and quadroma format had similar cytotoxic activity, with Tandab being the most active format. Tandab has also been claimed to be superior to single-chain (sc) Fv-based bispecific constructs although data from a side-by-side comparison are not available. In this study, we compared side-by-side MT103 (bscCD19xCD3), a single-chain bispecific antibody of the BiTE class, with a CD19-/CD3-bispecific representative of the Tandab class. Based on literature data, we have constructed, produced and characterized the LL linker version of Tandab, which was reported to be the most active version of Tandab proteins. A dimeric protein of 114kDa was obtained that showed proper bispecific binding to CD3- and CD19-positive cells and could redirect both pre-stimulated and unstimulated human T cells for lysis of human B lymphoma lines Raji, MEC-1 and Nalm-6. Raji cells were lysed at a half-maximal concentration (EC50) of 10 nM Tandab using pre-stimulated T cells, which closely matched the published activity of LL-Tandab with this particular cell line. MT103 had between 700- and 8000-fold higher efficacy than Tandab for redirected lysis of the three human B lymphoma lines. These data demonstrate that under identical experimental conditions, the BiTE format has far superior activity compared to the Tandab format and is also superior to conventional diabody and quadroma formats. The extraordinary potency of the BiTE class and its representative MT103 may translate into improved anti-tumor activity, lower dosing and lower costs of production compared to other bispecific antibody formats.

Comment in

• Flawed TandAb production.

  Little M, Kipriyanov S. Little M, et al. Mol Immunol. 2007 Apr;44(11):3083; author reply 3084. doi: 10.1016/j.molimm.2007.01.006. Epub 2007 Mar 6. Mol Immunol. 2007. PMID: 17339053 No abstract available.

Similar articles

• Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.

  Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J, Benner A, Moldenhauer G, Little M. Cochlovius B, et al. Cancer Res. 2000 Aug 15;60(16):4336-41. Cancer Res. 2000. PMID: 10969772

• A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.

  Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA. Reusch U, et al. MAbs. 2015;7(3):584-604. doi: 10.1080/19420862.2015.1029216. MAbs. 2015. PMID: 25875246 Free PMC article.

• Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.

  Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, Little M. Kipriyanov SM, et al. J Mol Biol. 1999 Oct 15;293(1):41-56. doi: 10.1006/jmbi.1999.3156. J Mol Biol. 1999. PMID: 10512714

• RECRUIT-TandAbs: harnessing the immune system to kill cancer cells.

  McAleese F, Eser M. McAleese F, et al. Future Oncol. 2012 Jun;8(6):687-95. doi: 10.2217/fon.12.54. Future Oncol. 2012. PMID: 22764766 Review.

• Recombinant bispecific antibodies for cancer therapy.

  Kontermann RE. Kontermann RE. Acta Pharmacol Sin. 2005 Jan;26(1):1-9. doi: 10.1111/j.1745-7254.2005.00008.x. Acta Pharmacol Sin. 2005. PMID: 15659107 Review.

Cited by

• Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies.

  Matlawska-Wasowska K, Ward E, Stevens S, Wang Y, Herbst R, Winter SS, Wilson BS. Matlawska-Wasowska K, et al. Leukemia. 2013 Jun;27(6):1263-74. doi: 10.1038/leu.2013.5. Epub 2013 Jan 11. Leukemia. 2013. PMID: 23307031 Free PMC article.

• The old CEACAMs find their new role in tumor immunotherapy.

  Han ZW, Lyv ZW, Cui B, Wang YY, Cheng JT, Zhang Y, Cai WQ, Zhou Y, Ma ZW, Wang XW, Peng XC, Cui SZ, Xiang Y, Yang M, Xin HW. Han ZW, et al. Invest New Drugs. 2020 Dec;38(6):1888-1898. doi: 10.1007/s10637-020-00955-w. Epub 2020 Jun 2. Invest New Drugs. 2020. PMID: 32488569 Review.

• Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies.

  Husain B, Ellerman D. Husain B, et al. BioDrugs. 2018 Oct;32(5):441-464. doi: 10.1007/s40259-018-0299-9. BioDrugs. 2018. PMID: 30132211 Free PMC article. Review.

• Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.

  Yoneyama T, Kim MS, Piatkov K, Wang H, Zhu AZX. Yoneyama T, et al. PLoS Comput Biol. 2022 Jul 15;18(7):e1009715. doi: 10.1371/journal.pcbi.1009715. eCollection 2022 Jul. PLoS Comput Biol. 2022. PMID: 35839267 Free PMC article.

• Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig.

  Bardwell PD, Staron MM, Liu J, Tao Q, Scesney S, Bukofzer G, Rodriguez LE, Choi CH, Wang J, Chang Q, Dong F, Donawho C, Wang J, Grinnell CM, Tarcsa E, Hutchins C, Ghayur T, Gu J. Bardwell PD, et al. Protein Cell. 2018 Jan;9(1):121-129. doi: 10.1007/s13238-017-0429-z. Epub 2017 Jun 5. Protein Cell. 2018. PMID: 28585177 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information